Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura
Bessmertniy,Dmitriy
DOI: https://doi.org/10.1055/s-0044-1791780
2024-10-18
Seminars in Thrombosis and Hemostasis
Abstract:Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening disease. iTTP develops due to autoantibodies to the ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) enzyme. These antibodies lead to functional deficiency of ADAMTS-13, which results in the circulation of ultra-large von Willebrand factor (VWF) multimers and leads to thrombocytopenia, hemolysis, and organ ischemia.[1] ADAMTS-13 autoantibodies can be triggered by certain antiplatelet drugs, immunosuppressive agents, human immunodeficiency virus (HIV), estrogen-containing contraceptives, and pregnancy. Initial iTTP treatment may include plasma exchange (PEX)[2] and immunosuppressive therapy (glucocorticoids and rituximab).[3] Such treatment increased the survival rate of patients with iTTP to 78%.[4] The introduction of caplacizumab has dramatically improved the results of iTTP treatment. Caplacizumab forms a part of so-called triplet therapy, which includes daily PEX from the first day until the platelet count is ≥150 × 10 9 /L, administration of immunosuppression (prednisolone 1 mg/kg and rituximab at a dose of 375 mg/m 2 intravenously on days 1, 4, 8 and 15) and caplacizumab. Caplacizumab is recommended for 30 days after cessation of PEX.[5] However, some patients may achieve remission earlier than the 30-day period, while others may require more than 30 days to reach an ADAMTS-13 activity level of ≥20%. Between February 2021 and March 2024, 24 patients were diagnosed with iTTP based on clinical manifestations, thrombocytopenia, hemolytic anemia, ADAMTS-13 activity level of less than 10%, and presence of the ADAMTS-13 inhibitor ([Table 1]). Data presented as median and range (difference between lowest and highest values). Characteristic Value Age, y, median (range) 43 (18–68) Female, n 18 (75%) De novo iTTP, n 20 (83%) iTTP relapse, n 4 (17%) Clinical presentations Neurological/mental disorders, n 15 (63%) Thrombocytopenia, n 24 (100%) Hemorrhagic syndrome, n 24 (100%) Anemia, n 24 (100%) ADAMTS-13 activity, %, median (range) 0 (0–3.1) ADAMTS-13 inhibitor, BU, median (range) 2.5 (0.4–14.0) Platelet count, ×10 9 /L, median (range) 18 (1–59) Hemoglobin, g/L, median (range) 81 (48–111) Schistocyte count, % median (range) 1 (0–13) LDH, U/L, median (range) 564 (281–3,025) PEX from suspicion of TTP to triplet therapy Number of patients, n 7/24 Number of PEX, median (range) 4 (1–8) Total volume, mL, median (range) 8,000 (2,000–16,000) Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; iTTP, immune thrombotic thrombocytopenic purpura; LDH, lactate dehydrogenase; PEX, plasma exchange; TTP, thrombotic thrombocytopenic purpura. After clinical suspicion of iTTP, prior to receiving the ADAMTS-13 activity results, 7 of 24 patients immediately underwent PEX procedures; however, these patients continued to exhibit thrombocytopenia, anemia, and clinical signs of iTTP before the start of the triplet therapy. We therefore modified the triplet therapy and tailored it based on the ADAMTS-13 activity. The modification of the triplet therapy included the time of initiation of treatment with rituximab and duration of therapy with caplacizumab and rituximab. After confirming the diagnosis of iTTP with ADAMTS-13/inhibitor testing, we initiated or continued treatment with daily PEX and started prednisolone (1 mg/kg/d) and caplacizumab. Patients received an intravenous loading dose of caplacizumab (10 mg) before the start of the first PEX. Subsequent doses (10 mg) were administered subcutaneously, once daily. Caplacizumab was provided free of charge via Sanofi's Managed Access Program. Sanofi was not involved in the design, collection, analysis, interpretation, or reporting of data, but was given the opportunity to review the publication prior to submission. The decision to submit for publication was made independently by the authors. We continued PEX until the platelet count increased to ≥150 × 10 9 /L, then we stopped PEX, but continued caplacizumab and prednisolone. Only after stopping PEX did we start rituximab (375 mg/m 2 intravenously once a weekly; [Fig. 1]). Caplacizumab was stopped only after the ADAMTS-13 activity reached ≥20% (partial ADAMTS-13 remission). Rituximab and prednisolone were continued until the ADAMTS-13 activity reached ≥40% (complete ADAMTS-13 remission), then rituximab was stopped and the dose of prednisolone was gradually tapered off. In the week after the triplet therapy, neurological and cognitive disorders had regressed in all previously affected patients. The median time from the start of t -Abstract Truncated-
peripheral vascular disease,hematology